The litigation centers on allegations that Nano-X provided misleading information regarding manufacturing efficiency and product demand. On April 20, 2026, the company’s share price fell by $0.695, closing at $2.155, after management revealed the closure of its South Korean chip production line. Joseph E. Levi, an attorney at Levi & Korsinsky, LLP, emphasized that identifying a lead plaintiff with a significant financial stake is essential to managing the prosecution of these claims and ensuring accountability for the losses incurred.
Nano-X Imaging Investors Face August 11 Deadline in Securities Lawsuit
Investors who purchased Nano-X Imaging Ltd. securities between March 31, 2025, and April 17, 2026, have until August 11, 2026, to file for lead plaintiff status in a pending class action. The legal push follows a 24.39% single-day stock drop triggered by a $17.5 million asset impairment and manufacturing restructuring disclosure.
Under the Private Securities Litigation Reform Act, the court will appoint a lead plaintiff to oversee the case, including settlement approvals and litigation strategy. Those who do not seek this appointment remain class members and retain their rights to participate in any potential recovery without taking immediate action. Applicants for lead plaintiff are not required to cover legal fees upfront, as counsel operates on a contingency basis. Investors interested in the role should gather brokerage documentation, including purchase dates and quantities, to evaluate their eligibility before the August 11 cutoff.
Comments (0)
No comments yet. Be the first!